Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The rapidly evolving stem cell space may have matured to the level where a single company’s misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following Osiris Therapeutics’ recent announcement that its mesenchymal stem cell therapy Prochymal produced mixed results in an interim look at a study of 62 patients with chronic obstructive pulmonary disease.